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Available online 1 June 2016Perampanel (PER) is theﬁrst-in-class selective, noncompetitiveα-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for
patients with partial-onset and primary generalized tonic–clonic seizures. A positive effectwas reported in some
patients with epileptic myoclonic jerks in idiopathic generalized epilepsy and in progressivemyoclonic epilepsy.
We treated amale patientwith posthypoxic nonepilepticmyoclonus (Lance–Adams syndrome)with add-on PER
and achieved an almost complete cessation of jerks. This effectwas reproducible and, therefore, we suggest that it
might be worth trying PER in comparable cases.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Efﬁcacy1. Introduction
Perampanel (PER) is the ﬁrst-in-class orally active antagonist of
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors [1,2]. Perampanel was licensed in Europe and the US for the
add-on treatment of patients with epilepsy with partial-onset seizures
after three phase III trials that assessed the clinical efﬁcacy and tolerabil-
ity of PER as adjunctive antiepileptic drug (AED) in patients with difﬁ-
cult-to-treat partial-onset epileptic seizures [3–6]. In addition, PER
was approved for the treatment of patients with primary generalized
tonic–clonic seizures because superiority over placebo was shown in a
randomized controlled trial [7]. In this trial, at least some patients re-
ported a beneﬁcial effect on additional myoclonic jerks. Furthermore,
single reports indicated a potential beneﬁcial effect of PER when used
in an off-labelmanner in Lafora disease, a formof progressivemyoclonic
epilepsy [8,9]. Experience in other indications is very limited. However,
our own clinical experience beyond the label and one report on convinc-
ing efﬁcacy of PER in a case of superrefractory acute posthypoxic
myoclonus [10] encouraged us to start add-on PER in a chronic case of
drug-resistant posthypoxic myoclonus (Lance–Adams syndrome).
2. Case report
This 36-year-oldmale had suffered from drug-resistant posthypoxic
myoclonus for one year after a cardiac arrest and reanimation because
of cardiologically proven Brugada syndrome.
On admission, he presented with almost continuous stimulus-
sensitive polytopic myoclonic jerks that required the permanent useandstraße 1, 77694 Kehl-Kork,
.
teinhoff).
. This is an open access article underof a wheelchair. Electroencephalography recordings were repeatedly
normal and showed no epileptiform discharges during myoclonic
jerks. We did not perform magnetic resonance imaging (MRI) because
a pacemaker with deﬁbrillator had been implanted. Previous computed
cerebral tomography (CCT) had not shown clinically relevant abnormali-
ties. His medication consisted of 2000 mg of levetiracetam, 1500 mg of
valproic acid, 2mg of clonazepam, and 7600mg of piracetam. In addition,
100 mg of lacosamide had been added few weeks prior to admission in
our hospital.
Perampanel was initiated at a dose of 2 mg and increased to 4 mg
once daily in the evening after three days. Myoclonic jerks were
suppressed almost completely after the dose increased to 4 mg. It was
possible to discontinue lacosamide and piracetam without complica-
tions. Since the patient complained about PER-related somnolence, he
wished to try a withdrawal. The next day, myoclonus was very promi-
nent again and remained over the followingﬁve days beforewe decided
to reintroduce PER (4 mg per day). Myoclonus was suppressed again
and has not been reported for the follow-up of 4 weeks. Somnolence
decreased and is tolerable now.
3. Discussion
Myoclonic jerks are frequent symptoms in several central nervous
diseases and conditions. They may not only be part of various epilepsy
syndromes but also occur as the result of nonepileptic pathogenesis as
a cerebellar phenomenon in patients with posthypoxic brain damage
which is well-known as so-called Lance–Adams syndrome. Although
the action myoclonus in Lance–Adams syndrome is usually not of epi-
leptic origin, antiepileptic drugs are recommended for its treatment
[11–15]. In addition, piracetam has been recommended [16]. Because
of the nonepileptic origin of the myoclonus, other therapeutic ap-
proaches addressed the idea of a movement disorder and suggestedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[18] including alcohol [19], sodium oxybate [20], baclofen [21], or deep-
brain stimulation [22,23]. The prognosis is bad; the efﬁcacy of AEDs is
usually limited.
In our patient, most recommended AEDs had already been tried in
vain. Therefore, it was tempting to speculate if PER might be a suitable
option since beneﬁcial effects have been reported in single patients
with juvenile myoclonic epilepsy [7] and Lafora disease [8,9] as well as
in an acute myoclonic status after severe hypoxia [10].
Somnolence and dizziness belong to the most common adverse
events under add-on PER [6,24]. The rather fast up-titration to 4 mg
was performed more quickly than generally recommended because
we wanted to estimate the potential efﬁcacy of PER in this severe case
with numerous myoclonic jerks as fast as possible. Therefore, somno-
lence might have been partly caused by this titration regimen. In
patients with epilepsy, a more cautious titration is useful in order to
avoid adverse events [25]. We discontinued PER in our case in spite of
the apparent beneﬁcial effect against the myoclonic jerks because of
the sedating effects the patient complained about. After discontinua-
tion, myoclonus exaggerated and was suppressed almost completely
again when we reintroduced PER. Interestingly, this time tolerability
was better, and so, we assume that a sort of adaptation had happened.
Because of the reproducible effect of add-on PER after reintroduction,
we are convinced about its efﬁcacy in our patient and recommend try-
ing it in comparable cases. Since patients with Lance–Adams syndrome
suffer from very frequentmyoclonus, one should be able to judge the ef-
ﬁcacy of PER rather promptly in spite of the long elimination half-life
and the considerable delay until plasma steady state is reached [25].
We hope that our patient will be able to cope with the sedating proﬁle
of PER. Long-term follow-up is not yet available.
4. Conclusion
This observation justiﬁes trying add-on PER beyond the labeling in
difﬁcult-to-treat cases of Lance–Adams syndrome on an individualized
basis.
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